TSC1-PL
HMSCATi008-A
General
Cell Line |
|
| hPSCreg name | HMSCATi008-A |
| Cite as: | HMSCATi008-A |
| Alternative name(s) |
TSC1-PL
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
IMBAi021-A (TSC107J #5, TSC#14 clone 107J#5) Donor's gene variants: TSC2, TSC2 Donor diseases: Tuberous Sclerosis IMBAi022-A (TSC112#4, TSC#24 clone 112#4) Donor's gene variants: TSC2, TSC2 Donor diseases: Tuberous Sclerosis IMBAi023-A (TSC#5 clone 32S, TSCp5#32S) Donor's gene variants: TSC2, TSC2 Donor diseases: Tuberous Sclerosis IMBAi023-B (TSC#5 clone 30S, TSCp5#30S, TSC98#30S) Donor's gene variants: TSC2, TSC2, TSC2 Donor diseases: Tuberous Sclerosis |
| Last update | 8th December 2024 |
| User feedback | |
Provider |
|
| Generator | Stem Cell Application and Translation Laboratory (HMSCAT) |
External Databases |
|
| BioSamples | SAMEA117485880 |
General Information |
|
| * Is the cell line readily obtainable for third parties? |
No |
Donor Information
General Donor Information |
|
| Sex | male |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
External Databases (Donor) |
|
| BioSamples | SAMEA117485881 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | No |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | anonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | Yes |
| How may genetic information associated with the cell line be accessed? | Controlled Access |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | Medical Ethics Committee of Hebei Medical University |
| Approval number | 2020054 |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
| Source cell type |
A peripheral blood cell with a single nucleus. This category includes lymphocytes and monocytes.
Synonyms
|
Reprogramming method |
|
| Vector type | Integrating |
| Vector | Plasmid |
| Genes | |
| Is the used vector excisable? |
Yes |
| Absence of reprogramming vector(s)? |
No |
| Reprogramming vectors silenced? |
Yes |
| Methods used |
RT-PCR
|
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
Unknown |
| Derived under GMP? |
No |
| Available as clinical grade? |
Unknown |
Culture Conditions
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Medium |
Other medium:
Base medium: ncTarget
Main protein source: Knock-out serum replacement Serum concentration: % |
Characterisation
Analysis of Undifferentiated Cells
Differentiation Potency
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.